Investor Group Says China's Sinovac Worth 75% More than Management's Offer

Heng Ren Investments of Boston believes Sinovac's management should raise its privatization offer for Sinovac by 75%: from $6.18 per share to $10.84. Just before management made its offer, Heng Ren says, Sinovac received China approval for its Hand, Foot and Mouth vaccine, a product with $400 million in potential revenues. Given that Sinovac. which is based in Beijing, posted $67 million in sales last year, the effect on Sinovac could be substantial. Heng Ren specializes in "orphan" China companies listed in the US and has a position in Sinovac. More details.... Stock Symbol: (NSDQ: SVA) Share this with colleagues: // //